WEBULL
News
GPCR
75.98
-3.27%
-2.57
Weekly Report: what happened at GPCR last week (0202-0206)?
Weekly Report · 2d ago
BUZZ-Novo Nordisk, obesity firms drop on report of Hims Wegovy pill copy launch
Reuters · 6d ago
Piper Sandler Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
TipRanks · 6d ago
BUZZ-US-listed Novo shares slip after company flags sharp 2026 sales drop
Reuters · 02/03 17:48
STRUCTURE THERAPEUTICS DOWN 5.3%, VIKING THERAPEUTICS DOWN 3.3%, AMGEN DOWN 1.4%
Reuters · 02/03 17:33
OBESITY DRUGMAKERS AND DEVELOPERS FALL AFTER RIVAL NOVO NORDISK WARNS OF STEEP 2026 SALES DECLINE
Reuters · 02/03 17:33
Weekly Report: what happened at GPCR last week (0126-0130)?
Weekly Report · 02/02 09:09
Key deals this week: Apple, McEwen Mining, IonQ, Leidos, and more
Seeking Alpha · 01/31 20:15
Structure Therapeutics gains on report suggesting it may be a top takeover target
Seeking Alpha · 01/30 17:55
Midday Fly By: Warsh nominated for Fed chair, Apple reports Q1 beat
TipRanks · 01/30 17:01
Structure Therapeutics emerges as top M&A target for big pharma, Axios says
TipRanks · 01/30 15:51
'Structure Therapeutics could be pharma's next buyout candidate'- Axios
Benzinga · 01/30 15:44
Weekly Report: what happened at GPCR last week (0119-0123)?
Weekly Report · 01/26 09:09
Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It
Benzinga · 01/23 14:18
Structure Therapeutics Is Maintained at Overweight by JP Morgan
Dow Jones · 01/22 16:51
Structure Therapeutics Price Target Raised to $105.00/Share From $65.00 by JP Morgan
Dow Jones · 01/22 16:51
JP Morgan Maintains Overweight on Structure Therapeutics, Raises Price Target to $105
Benzinga · 01/22 16:43
Structure Therapeutics price target raised to $105 from $65 at JPMorgan
TipRanks · 01/22 11:51
STRUCTURE THERAPEUTICS INC <GPCR.O>: JP MORGAN RAISES TARGET PRICE TO $105 FROM $65
Reuters · 01/22 05:26
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Goldman Sachs
TipRanks · 01/20 15:58
More
Webull provides a variety of real-time GPCR stock news. You can receive the latest news about Structure Therapeutics Inc ADR through multiple platforms. This information may help you make smarter investment decisions.
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.